PennyStocksUpdate.biz is devoted to fetch you the most exclusive stocks in the market today. Apart from scanning the markets for the most underrated stocks. We propel those victors directly to your email inbox first ahead of the rest of the marketplace gets a prospect.
New York, NY -- (SBWIRE) -- 01/17/2013 -- Green Dot (NASDAQ:GDOT) had its target price increased by Compass Point from $10.00 to $13.00. They currently have a neutral rating on the stock. The analysts wrote, “Following the company’s unveiling of GoBank we are updating our views. Both our Neutral rating and $1.31 FY’12 EPS estimates remain unchanged. However, we are revising our FY’13 EPS estimate to $1.00 ($0.76 previously) resulting in a new price target of $13 ($10 previously). The new mobile account offering is feature rich and targets a new end market. However, at this point, there is a lack of visibility into the size and timing of any incremental benefit. In aggregate, there remains enough uncertainty in front of the company that we remain cautious.
To the downside, increasing competition may pressure GPR card pricing as well as new card sales. The inability to sell new cards would be magnified by high churn rates. On the other hand, management is striving to generate sustainable earnings through serving unique niches within the broader banking market as demonstrated by the GoBank launch. With the shares +59% of the 52 low, we commend investors who bought the steep sell off, but remain comfortable with our existing recommendation as of 4/27/12 to remain on the sidelines during this transitional period.”
How Should Investors React To GDOT Now? Find Out Here
MELA Sciences, Inc. (NASDAQ:MELA) shares gained 4.95% to $2.12. The company announced that it will be participating in the upcoming Needham Growth Conference, being held January 15 – 17, 2013 at the Palace Hotel in New York. Joseph V. Gulfo, MD, MELA Sciences President and CEO will be presenting at the conference on Wednesday, January 16 at 10:00am ET.
Is MELA Ready To Move Back To New Highs This Year? Find Out Here
Northern Trust Co (NASDAQ:NTRS) is very active today and traded between $49.27 - 51.39 with total traded volume of 4488306 shares. At a current price of 49.78, NTRS is -3.03 - -5.74% from the previous close of $52.81. Moreover, At Current Market Price, NTRS is in distance of -0.06% from its 50-day Moving Average price of $49.8091 and +4.57% from its 200-day Moving Average price of $47.604.
For a FREE NTRS Technical Analysis, please visit here
Orexigen Therapeutics, Inc. (NASDAQ:OREX) shares increased 5.09% to $6.61 in yesterday’s session. The company, on Jan. 7, announced announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave(®) (naltrexone SR / bupropion SR) New Drug Application (NDA).
Additionally, Piper Jaffray initiated coverage on shares of OREX in a research note released on Jan. 3. The firm issued an overweight rating on the stock.
Can OREX Rebound After The Recent Slump and Investors Can Make Money? Find Out Here
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)